Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD20 in Relapsed or Refractory Follicular Lymphoma
NCT00092274Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Sep 2004
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in follicular lymphoma (FL), sponsored by GSK. Primary endpoints: Safety and Adverse Events and Objective Response Rate. Planned start Sep 2004; status: withdrawn.
02
Drugs
ofatumumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00092274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092274.